OBJECTIVE: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). METHODS: Patients (n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. RESULTS: After 108 weeks, increase in total lesion volume was 67.4% (p=0.0003) and 39.4% (p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. CONCLUSIONS:Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.
RCT Entities:
OBJECTIVE: The purpose of this study was to determine the effects of oral teriflunomide on multiple sclerosis (MS) pathology inferred by magnetic resonance imaging (MRI). METHODS:Patients (n=1088) with relapsing MS were randomized to once-daily teriflunomide 7 mg or 14 mg, or placebo, for 108 weeks. MRI was recorded at baseline, 24, 48, 72 and 108 weeks. Annualized relapse rate and confirmed progression of disability (sustained ≥12 weeks) were the primary and key secondary outcomes. The principal MRI outcome was change in total lesion volume. RESULTS: After 108 weeks, increase in total lesion volume was 67.4% (p=0.0003) and 39.4% (p=0.0317) lower in the 14 and 7 mg dose groups versus placebo. Other measures favoring teriflunomide were accumulated enhanced lesions, combined unique activity, T2-hyperintense and T1-hypointense component lesion volumes, white matter volume, and a composite MRI score; all were significant for teriflunomide 14 mg and most significant for 7 mg versus placebo. CONCLUSIONS:Teriflunomide provided benefits on brain MRI activity across multiple measures, with a dose effect evident on several markers. These effects were also consistent across selected subgroups of the study population. These findings complement clinical data showing significant teriflunomide-related reductions in relapse rate and disease progression, and demonstrate containment of MRI-defined disease progression.
Entities:
Keywords:
Teriflunomide; clinical trial; disease-modifying therapy; magnetic resonance imaging; multiple sclerosis; phase III
Authors: Fred D Lublin; Stacey S Cofield; Gary R Cutter; Tarah Gustafson; Stephen Krieger; Ponnada A Narayana; Flavia Nelson; Amber R Salter; Jerry S Wolinsky Journal: Mult Scler Relat Disord Date: 2017-09-23 Impact factor: 4.339
Authors: David H Miller; Robert J Fox; J Theodore Phillips; Michael Hutchinson; Eva Havrdova; Mariko Kita; Claudia A M Wheeler-Kingshott; Daniel J Tozer; David G MacManus; Tarek A Yousry; Mary Goodsell; Minhua Yang; Ray Zhang; Vissia Viglietta; Katherine T Dawson Journal: Neurology Date: 2015-02-13 Impact factor: 9.910
Authors: Amit Bar-Or; Mark S Freedman; Marcelo Kremenchutzky; Françoise Menguy-Vacheron; Deborah Bauer; Stefan Jodl; Philippe Truffinet; Myriam Benamor; Scott Chambers; Paul W O'Connor Journal: Neurology Date: 2013-07-12 Impact factor: 9.910
Authors: Paul W O'Connor; Fred D Lublin; Jerry S Wolinsky; Christian Confavreux; Giancarlo Comi; Mark S Freedman; Tomas P Olsson; Aaron E Miller; Catherine Dive-Pouletty; Gaëlle Bégo-Le-Bagousse; Ludwig Kappos Journal: J Neurol Date: 2013-07-14 Impact factor: 4.849